Current work
I am the CEO of Impelix Health Inc., a medical device company developing a wearable bioimpedance system for monitoring peripheral edema in heart failure, cirrhosis, and kidney disease — conditions in which fluid status drives hospitalizations, and in which earlier, quantified detection can change outcomes. A first-in-human study is planned at CISSS des Laurentides (Saint-Jérôme) for 2026–27, building on my 2025 systematic review of bioimpedance for edema assessment.
Clinically, I am staff internist at Hôpital régional de Saint-Jérôme (CISSS des Laurentides), where I have practiced since 2012 — CCU attending, ward and emergency consultation, and a full-scope general internal medicine clinic that, in a regional hospital without on-site endocrinology or rheumatology, spans the community scope of those specialties. Since 2026 I have also served as a locum internist in Ontario (ICU, emergency consultation, ward).
I am also a co-founder of Bravella Health, a women's-health company incorporated in September 2024 after an extended concept-development phase, where I served as Chief Medical Officer until June 2025, when the company recruited an obstetrician-gynecologist with subspecialty training in menopause medicine for the role. I continue as a co-founder and clinical advisor, contributing clinical education to the team — most recently on metabolic medicine and the GLP-1 receptor agonist landscape.
Writing & publications
I write on medicine, technology, and health policy. I was a regular op-ed contributor to the Montreal Gazette (2018–2019) and a contributor to The Washington Post — Mental health assessments should not be done by an algorithm (2018).
Selected clinical publications:
Tubana-Dean S, Hofmann A, Razzicchia E, Porter E. Bioimpedance for peripheral edema assessment in heart failure and clinical practice: a systematic review. Physiol Meas. 2025;46(11):11TR01.
Hofmann A, Beaulieu Y, Bernard F, Rico P. Fulminant legionellosis in two patients treated with infliximab for Crohn's disease: case series and literature review. Can J Gastroenterol. 2009;23(12):829–33.
Silver EA, Hofmann AE, Williams D, Srolovitz H, Tahiri Y, Khanna M. Large amelanotic melanoma and vitiligo. Arch Dermatol. 2009;145(10):1198–9.
Hofmann A, Zaharatos G, Miller M. Toxoplasma gondii encephalitis in a 40-year-old woman with common variable immunodeficiency and a new diagnosis of large granular lymphocytic leukemia. Can J Infect Dis Med Microbiol. 2008;19(4):309–10.
Hofmann A, Tangri N, Lafontaine AL, Postuma RB. Myoclonus as an acute complication of low-dose hydromorphone in multiple system atrophy. J Neurol Neurosurg Psychiatry. 2006;77(8):994–5.
Worgan LC, Niles K, Tirone JC, Hofmann A, et al. Spectrum of mutations in mut methylmalonic acidemia and identification of a common Hispanic mutation and haplotype. Hum Mutat. 2006;27(1):31–43.
Teaching & service
I have been a clinical teacher with the Université de Montréal Faculty of Medicine since 2009, regularly supervising senior general internal medicine residents, and was named Teacher of the Year at Hôpital du Sacré-Cœur de Montréal (2010–2011). I served as an elected board member of the Québec Medical Association (2018–2020) and as resident member of the board of directors of the SMBD Jewish General Hospital (2006–2009). As a medical student I founded the Asclepius Project, a humanistic-medicine society recognized with a Forces Avenir award (no longer active), and trained as a clown-doctor with the Gesundheit Institute, including fieldwork alongside Patch Adams. My teaching interests centre on clinical communication — including a medical-improv curriculum on reading the room in patient encounters — and on how physicians can build, rather than merely inhabit, the systems they work in.
Contact
I can be reached at hofmann.adam@gmail.com. A factual summary of my professional background and record, including public register links for licensure verification, is maintained at adamhofmann.ca/background.